Atai Life Sciences N.V. (ATAI) Stock Price, Quote & News

Company Profile

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 282 0507

Website: www.ataibeckley.com

Address:

250 West 34th Street, New York, United States

PeaceLoveAndHarmony May. 19 at 7:07 PM

$ATAI placed some coins 😇 💞

0 · Reply

brunoq14 May. 19 at 6:49 PM

$ATAI I believe we have a drug update and a Phase 3 trial launch coming up quite soon.

2 · Reply

OmFm May. 19 at 2:21 PM

$ATAI buying more at this price.

0 · Reply

duhbledown11 May. 19 at 2:06 PM

$ATAI man wtf is going on here

2 · Reply

OmFm May. 19 at 1:44 PM

$ATAI expect anything else? Classic!

0 · Reply

TheVisona May. 19 at 12:43 PM

$ATAI

0 · Reply

BobbyCucumber May. 19 at 3:00 AM

$ATAI

0 · Reply

Psychedelic_Stonks May. 18 at 7:51 PM

$ATAI

0 · Reply

Hammy111 May. 18 at 7:40 PM

$ATAI patience lads.. patience. Need conviction, or this isn’t the play for you. It’s a strong company that will be stronger in the future. Sky is the limit.

0 · Reply

Morpheus87 May. 18 at 6:21 PM

$ATAI should have bet on that this gives everything away intraday once again…

0 · Reply

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

CMND CMPS DFTX ENVB GHRS MIRA NRXP

2026-05-12T16:08:09.000Z - 7 days ago

AtaiBeckley reports Q1 EPS (8c), consensus (11c)

May 12, 2026, 8:00 AM EDT - 7 days ago

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

May 12, 2026, 7:00 AM EDT - 7 days ago

AtaiBeckley Quarterly report: Q1 2026

May 9, 2026, 11:53 AM EDT - 10 days ago

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

ACTU VVOS

Apr 27, 2026, 11:15 AM EDT - 22 days ago

These 3 Psychedelic Stocks Activated After Trump's Executive Order

CMPS DFTX

Apr 27, 2026, 11:00 AM EDT - 22 days ago

AtaiBeckley Transcript: Needham Virtual Psychedelics Forum

Apr 27, 2026, 4:05 AM EDT - 22 days ago

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

Apr 22, 2026, 8:00 AM EDT - 27 days ago

AtaiBeckley Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 27 days ago

AtaiBeckley Proxy statement: Proxy filing

Apr 22, 2026, 6:00 AM EDT - 27 days ago

AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder

Apr 20, 2026, 3:05 PM EDT - 4 weeks ago

This 4/20, Wall Street Is Betting on More Than Marijuana

CMPS

Apr 20, 2026, 2:05 PM EDT - 4 weeks ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

CMPS DFTX HELP GHRS

Apr 20, 2026, 10:45 AM EDT - 4 weeks ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

CMPS DFTX GHRS

2026-04-20T13:22:59.000Z - 4 weeks ago

AtaiBeckley price target raised to $15 from $14 at Canaccord

Apr 20, 2026, 8:26 AM EDT - 4 weeks ago

Psychedelic stocks rally with Trump's support

CMPS DFTX GHRS

Apr 20, 2026, 8:18 AM EDT - 4 weeks ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

CMPS GHRS DFTX

Apr 20, 2026, 6:43 AM EDT - 4 weeks ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

CMPS DFTX ENVB GHRS HELP

2026-04-17T12:28:41.000Z - 4 weeks ago

AtaiBeckley price target raised to $16 from $11 at Guggenheim

Apr 16, 2026, 12:45 PM EDT - 4 weeks ago

AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 6:00 AM EDT - 5 weeks ago

AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences

2026-04-09T15:00:20.000Z - 5 weeks ago

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

NRXP PBM SILO

2026-04-08T10:07:08.000Z - 5 weeks ago

AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study

Apr 8, 2026, 6:00 AM EDT - 5 weeks ago

AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

2026-03-27T08:55:15.000Z - 7 weeks ago

AtaiBeckley initiated with a Buy at Deutsche Bank

2026-03-26T23:25:13.000Z - 7 weeks ago

AtaiBeckley initiated with a Buy at Deutsche Bank

Mar 24, 2026, 6:00 AM EDT - 2 months ago

AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst

2026-03-19T15:45:21.000Z - 2 months ago

Psychedelic: AtaiBeckley reports publication of BPL-003 study results

CMND ENVB IXHL JAGX NRXP SPRC

Mar 11, 2026, 8:00 AM EDT - 2 months ago

AtaiBeckley Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 6:00 AM EDT - 2 months ago

BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Mar 6, 2026, 12:30 PM EST - 2 months ago

AtaiBeckley Earnings release: Q4 2025

Mar 6, 2026, 12:30 PM EST - 2 months ago

AtaiBeckley Annual report: Q4 2025

Mar 6, 2026, 9:00 AM EST - 2 months ago

AtaiBeckley Transcript: Investor Day 2026

Mar 6, 2026, 9:00 AM EST - 2 months ago

AtaiBeckley Slides: FY 2026

Mar 6, 2026, 7:00 AM EST - 2 months ago

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Mar 4, 2026, 11:50 AM EST - 2 months ago

AtaiBeckley Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

AtaiBeckley Transcript: Study result

Feb 26, 2026, 8:00 AM EST - 2 months ago

AtaiBeckley Press release: Study result

Feb 26, 2026, 8:00 AM EST - 2 months ago

AtaiBeckley Slides: Study result

Feb 26, 2026, 7:00 AM EST - 2 months ago

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

Feb 20, 2026, 7:00 AM EST - 3 months ago

AtaiBeckley To Host Virtual Investor Day on March 6, 2026

Jan 19, 2026, 11:28 AM EST - 4 months ago

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

CRMD EVMN

Jan 16, 2026, 7:00 AM EST - 4 months ago

AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation

Jan 8, 2026, 7:00 AM EST - 4 months ago

AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Dec 23, 2025, 7:00 AM EST - 5 months ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

Nov 20, 2025, 6:30 AM EST - 6 months ago

AtaiBeckley Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 7:32 PM EST - 6 months ago

Enhanced Fortifies Executive Leadership Team & Board of Directors

Nov 12, 2025, 7:00 AM EST - 6 months ago

AtaiBeckley Quarterly report: Q3 2025

Nov 12, 2025, 7:00 AM EST - 6 months ago

AtaiBeckley Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 6 months ago

AtaiBeckley Transcript: Study Result

Nov 10, 2025, 8:00 AM EST - 6 months ago

AtaiBeckley Press release: Study Result

Nov 10, 2025, 8:00 AM EST - 6 months ago

AtaiBeckley Slides: Study Result

Oct 20, 2025, 5:29 PM EDT - 7 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Oct 16, 2025, 10:31 PM EDT - 7 months ago

atai Life Sciences Announces Pricing of Public Offering of Common Shares

Oct 16, 2025, 4:12 PM EDT - 7 months ago

atai Life Sciences Announces Proposed Public Offering of Common Shares

Oct 16, 2025, 4:10 PM EDT - 7 months ago

atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression

Oct 16, 2025, 8:00 AM EDT - 7 months ago

AtaiBeckley Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 7 months ago

AtaiBeckley Proxy statement: Proxy Filing

Sep 29, 2025, 8:00 AM EDT - 8 months ago

AtaiBeckley Proxy statement: Proxy Filing

Sep 24, 2025, 8:00 AM EDT - 8 months ago

AtaiBeckley Proxy statement: Proxy Filing

Sep 23, 2025, 8:00 AM EDT - 8 months ago

AtaiBeckley Proxy statement: Proxy Filing

Sep 23, 2025, 7:00 AM EDT - 8 months ago

atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression

Sep 17, 2025, 10:00 AM EDT - 8 months ago

AtaiBeckley Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 8, 2025, 11:30 AM EDT - 9 months ago

AtaiBeckley Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:35 AM EDT - 9 months ago

AtaiBeckley Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 4:05 PM EDT - 9 months ago

atai Life Sciences to Participate in September Investor Conferences

Aug 14, 2025, 8:00 AM EDT - 9 months ago

AtaiBeckley Proxy statement: Proxy Filing

Aug 14, 2025, 7:00 AM EDT - 9 months ago

AtaiBeckley Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 9 months ago

AtaiBeckley Quarterly report: Q2 2025

Jul 25, 2025, 4:16 PM EDT - 10 months ago

Atai Life Sciences schizophrenia drug fails to meet main goal in mid-stage trial

Jul 25, 2025, 4:05 PM EDT - 10 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Jul 2, 2025, 8:30 AM EDT - 11 months ago

AtaiBeckley Slides: Corporate Presentation

Jul 2, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Proxy statement: Proxy Filing

Jul 2, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Proxy statement: Proxy Filing

Jul 1, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Transcript: Study Update

Jul 1, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Press release: Study Update

Jul 1, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Slides: Study Update

Jul 1, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Proxy statement: Proxy Filing

Jul 1, 2025, 6:05 AM EDT - 11 months ago

atai Life Sciences Announces $50 Million Private Placement Financing

Jul 1, 2025, 6:00 AM EDT - 11 months ago

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Jun 18, 2025, 8:00 AM EDT - 11 months ago

AtaiBeckley Proxy statement: Proxy Filing

Jun 17, 2025, 7:00 AM EDT - 1 year ago

AtaiBeckley Transcript: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 9:55 AM EDT - 1 year ago